Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Poxel SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Poxel SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Poxel SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Poxel SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Poxel SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Poxel SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Poxel Acquires DRX-065 from DeuteRx 11
Venture Financing 12
Poxel Raises Additional USD13 Million in Series B Venture Financing 12
Poxel Raises US$17 Million In Series B Financing 13
Partnerships 14
Enyo Pharma Enters into Agreement with Poxel 14
Poxel Enters into Agreement with INC Research 15
Licensing Agreements 16
Roivant Sciences Enters into Licensing Agreement with Poxel 16
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 17
ENYO Pharma Enters into Licensing Agreement with Poxel 18
Equity Offering 19
Poxel to Raise USD15 Million in Private Placement of Shares 19
Poxel Raises USD29.3 Million in Private Placement of Shares 20
Poxel Plans to Raise Funds through IPO 21
POXEL Raises USD21.9 Million in Private Placement of Shares 22
Poxel Raises USD29 Million in IPO 23
Acquisition 24
Merck Sante Sells 4.74% Stake in Poxel 24
Poxel SA – Key Competitors 25
Poxel SA – Key Employees 26
Poxel SA – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Financial Announcements 28
Oct 16, 2018: Poxel reports third quarter and nine months 2018 financial update 28
Sep 19, 2018: Poxel announces financial results for the first half 2018 and provides corporate update 30
Jul 10, 2018: Poxel Announces Second Quarter and First Half 2018 Financial Update 33
Apr 23, 2018: Poxel Reports First Quarter 2018 Financial Results 34
Mar 22, 2018: Poxel Provides Business Update and Reports Results for Full Year 2017 35
Sep 21, 2017: Poxel Reports Results for the First Half 2017 and Provides Corporate Update 38
Jul 10, 2017: Poxel Announces Second Quarter 2017 Financial Update 41
May 04, 2017: Poxel Announces First Quarter 2017 Financial Update 42
Apr 03, 2017: Poxel Reports Results for Fiscal Year 2016 and Provides Corporate Update 43
Jan 27, 2017: Poxel Announces Fourth Quarter 2016 Financial Update 45
Corporate Communications 47
Jul 11, 2017: Poxel Appoints Kumi Sato to its Board of Directors 47
Apr 25, 2017: Poxel Announces Appointment of Anne Renevot as Chief Financial Officer 48
Mar 07, 2017: Poxel Announces Appointment of Christophe Arbet-Engels, MD, PhD, MBA, as Chief Medical Officer and EVP Late Development & Medical Affairs, Based in Boston 49
Product News 50
04/20/2017: Poxel to Present New Imeglimin Data at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes in Japan 50
03/21/2017: Poxel Announces Positive Results for Thorough QT Safety Clinical Study of Imeglimin 51
03/14/2018: DeuteRx to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference 52
Clinical Trials 53
Nov 12, 2018: Poxel presents promising data for PXL065 for the treatment of NASH at the American Association for the Study of Liver Diseases Meeting 53
Dec 27, 2017: Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan 55
Sep 20, 2017: Poxel Announces PXL770 Advances into a Phase 1b Multiple Ascending Dose Trial 57
Sep 14, 2017: Poxel Presents Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes at the European Association for the Study of Diabetes 53rd Annual Meeting 58
Sep 06, 2017: Poxel to Present Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes at the European Association for the Study of Diabetes 53rd Annual Meeting 60
Aug 28, 2017: Poxel Presents New Preclinical Imeglimin Data Demonstrating Improvement of Both Peripheral and Coronary Vascular Function at the European Society of Cardiology Congress 61
Jun 12, 2017: Poxel Presents New Preclinical Imeglimin Data on Improvement in Diastolic Function at the American Diabetes Association Meeting 62
Jun 06, 2017: Poxel Announces Additional Positive Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes 63
May 30, 2017: Poxel to Present New Preclinical Imeglimin Data on Protective Benefits from Diabetic Cardiomyopathy at the American Diabetes Association Meeting 64
May 22, 2017: Poxel Presents Imeglimin Japanese Phase 1 Results and Mechanistic Data at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes in Japan 65
May 04, 2017: Poxel Announces Positive Top Line Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes 66
Other Significant Developments 67
Jan 22, 2018: Poxel Announces Fourth Quarter 2017 Financial Update 67
Oct 16, 2017: Poxel Announces Third Quarter 2017 Financial Update 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69
Poxel SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Poxel SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Poxel SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Poxel SA, Deals By Therapy Area, 2012 to YTD 2018 9
Poxel SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Poxel Acquires DRX-065 from DeuteRx 11
Poxel Raises Additional USD13 Million in Series B Venture Financing 12
Poxel Raises US$17 Million In Series B Financing 13
Enyo Pharma Enters into Agreement with Poxel 14
Poxel Enters into Agreement with INC Research 15
Roivant Sciences Enters into Licensing Agreement with Poxel 16
Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 17
ENYO Pharma Enters into Licensing Agreement with Poxel 18
Poxel to Raise USD15 Million in Private Placement of Shares 19
Poxel Raises USD29.3 Million in Private Placement of Shares 20
Poxel Plans to Raise Funds through IPO 21
POXEL Raises USD21.9 Million in Private Placement of Shares 22
Poxel Raises USD29 Million in IPO 23
Merck Sante Sells 4.74% Stake in Poxel 24
Poxel SA, Key Competitors 25
Poxel SA, Key Employees 26
List of Figures
Poxel SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Poxel SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Poxel SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Poxel SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Poxel SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9